UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Ki67 in breast cancer: prognostic and predictive potential

The lancet oncology, 2010-02, Vol.11 (2), p.174-183

2010

Volltextzugriff (PDF)

Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars

Drugs (New York, N.Y.), 2020-11, Vol.80 (17), p.1811-1830

2020

Volltextzugriff (PDF)

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

The lancet oncology, 2011-09, Vol.12 (9), p.852-861

2011

Volltextzugriff (PDF)

Recommendations for genetic testing to reduce the incidence of anthracycline‐induced cardiotoxicity

British journal of clinical pharmacology, 2016-09, Vol.82 (3), p.683-695

2016

Volltextzugriff (PDF)

Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy

Journal of clinical oncology, 2010-03, Vol.28 (7), p.1138-1144

2010

Volltextzugriff (PDF)

Comparison of breast cancer recurrence and outcome patterns between patients treated from 1986 to 1992 and from 2004 to 2008

Journal of clinical oncology, 2015-01, Vol.33 (1), p.65-73

2015

Volltextzugriff (PDF)

Induction of autophagy is an early response to gefitinib and a potential therapeutic target in breast cancer

PloS one, 2013-10, Vol.8 (10), p.e76503

2013

Volltextzugriff (PDF)

Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31

Journal of clinical oncology, 2015-05, Vol.33 (14), p.1574-1583

2015

Volltextzugriff (PDF)

Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163

Journal of clinical oncology, 2009-09, Vol.27 (27), p.4536-4541

2009

Volltextzugriff (PDF)

Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27—A Randomized Controlled Phase III Trial

Journal of clinical oncology, 2013-04, Vol.31 (11), p.1398-1404

2013

Volltextzugriff (PDF)

Metformin, placebo, and endocrine therapy discontinuation among participants in a randomized double-blind trial of metformin vs placebo in hormone receptor-positive early-stage breast cancer (CCTG MA32)

Breast cancer research and treatment, 2023-07, Vol.200 (1), p.93-102

2023

Volltextzugriff (PDF)

Cardiac Safety Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial

Journal of clinical oncology, 2008-03, Vol.26 (8), p.1231-1238

2008

Volltextzugriff (PDF)

Does age affect outcome with breast cancer?

Breast (Edinburgh), 2023-08, Vol.70, p.25-31

2023

Volltextzugriff (PDF)

Expert Discussion: ASCO 2021

Breast care (Basel, Switzerland), 2021-08, Vol.16 (4), p.429-432

2021

Volltextzugriff (PDF)

Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents

Breast cancer research and treatment, 2011-02, Vol.126 (1), p.215-220

2011

Volltextzugriff (PDF)

Differential expression and prognostic relevance of autophagy-related markers ATG4B, GABARAP, and LC3B in breast cancer

Breast cancer research and treatment, 2020-10, Vol.183 (3), p.525-547

2020

Volltextzugriff (PDF)

Population-Based Validation of the Prognostic Model ADJUVANT! for Early Breast Cancer

Journal of clinical oncology, 2005-04, Vol.23 (12), p.2716-2725

2005

Volltextzugriff (PDF)

Cancer Treatment–Induced Bone Loss in Breast and Prostate Cancer

Journal of clinical oncology, 2008-11, Vol.26 (33), p.5465-5476

2008

Volltextzugriff (PDF)

Improving Care for Older Adults with Cancer in Canada: A Call to Action

Current oncology (Toronto), 2024-07, Vol.31 (7), p.3783-3797

2024

Volltextzugriff (PDF)

Safety, Pharmacokinetics, and Efficacy of CPX-1 Liposome Injection in Patients with Advanced Solid Tumors

Clinical cancer research, 2009-01, Vol.15 (2), p.692-700

2009

Volltextzugriff (PDF)

Further Investigation of the Role of ACYP2 and WFS1 Pharmacogenomic Variants in the Development of Cisplatin-Induced Ototoxicity in Testicular Cancer Patients

Clinical cancer research, 2018-04, Vol.24 (8), p.1866-1871

2018

Volltextzugriff (PDF)

Key Considerations for the Treatment of Advanced Breast Cancer in Older Adults: An Expert Consensus of the Canadian Treatment Landscape

Current oncology (Toronto), 2023-12, Vol.31 (1), p.145-167

2023

Volltextzugriff (PDF)

Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain

Current oncology (Toronto), 2022-12, Vol.29 (12), p.9891-9895

2022

Volltextzugriff (PDF)

Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on "Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29 , 9891-9895"

Current oncology (Toronto), 2023-05, Vol.30 (5), p.5050-5053

2023

Volltextzugriff (PDF)

Reply to Y. Wang et al and Q. Sui et al

Journal of clinical oncology, 2023-07, Vol.41 (21), p.3765-3766

2023

Volltextzugriff (PDF)

1 – 25 von 465

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(449)
Mit Volltextzugriff
(427)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(465)

Erscheinungsjahr

n.n

Thema

Science & Technology
(277)
Life Sciences & Biomedicine
(268)
Humans
(236)
Oncology
(219)
Female
(207)
Breast Cancer
(122)
Middle Aged
(121)
Breast Neoplasms - Drug Therapy
(114)
Breast Neoplasms - Pathology
(101)
Adult
(94)
Aged
(91)
Biological And Medical Sciences
(86)
Medical Sciences
(84)
Tumors
(84)
Chemotherapy
(61)
Gynecology. Andrology. Obstetrics
(51)
Mammary Gland Diseases
(51)
Treatment Outcome
(48)
Cancer Therapies
(44)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(43)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Ki67 in breast cancer: prognostic and predictive potential

Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

Recommendations for genetic testing to reduce the incidence of anthracycline‐induced cardiotoxicity

Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy

Comparison of breast cancer recurrence and outcome patterns between patients treated from 1986 to 1992 and from 2004 to 2008

Induction of autophagy is an early response to gefitinib and a potential therapeutic target in breast cancer

Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31

Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163

Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27—A Randomized Controlled Phase III Trial

Metformin, placebo, and endocrine therapy discontinuation among participants in a randomized double-blind trial of metformin vs placebo in hormone receptor-positive early-stage breast cancer (CCTG MA32)

Cardiac Safety Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial

Does age affect outcome with breast cancer?

Expert Discussion: ASCO 2021

Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents

Differential expression and prognostic relevance of autophagy-related markers ATG4B, GABARAP, and LC3B in breast cancer

Population-Based Validation of the Prognostic Model ADJUVANT! for Early Breast Cancer

Cancer Treatment–Induced Bone Loss in Breast and Prostate Cancer

Improving Care for Older Adults with Cancer in Canada: A Call to Action

Safety, Pharmacokinetics, and Efficacy of CPX-1 Liposome Injection in Patients with Advanced Solid Tumors

Further Investigation of the Role of ACYP2 and WFS1 Pharmacogenomic Variants in the Development of Cisplatin-Induced Ototoxicity in Testicular Cancer Patients

Key Considerations for the Treatment of Advanced Breast Cancer in Older Adults: An Expert Consensus of the Canadian Treatment Landscape

Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain

Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on "Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29 , 9891-9895"

Reply to Y. Wang et al and Q. Sui et al

Suchergebnisse filtern